UTHR Form 144: Martine Rothblatt plans 4,000‑share sale via TD Securities

Rhea-AI Filing Summary

United Therapeutics (UTHR) insider sale notice: An officer/director filed a Form 144 proposing the sale of 4,000 common shares through TD Securities (USA) LLC on 10/06/2025

The filing shows an aggregate market value of $1,798,765.20 for the 4,000 shares and reports the original acquisition on 03/15/2016 via executive deferred compensation consisting of 294,000 shares from Martine Rothblatt. The notice also lists multiple recent open-market sales by the same person between 09/09/2025 and 10/03/2025, with per-day sale quantities of 4,000 shares (one 8,000-share sale on 09/09/2025) and gross proceeds shown for each date. The filer certifies no undisclosed material information and identifies broker details and share counts but does not state total outstanding shares beyond the single row count of 45,230,000.

Positive

• Transparent disclosure of planned sale with broker and per‑trade gross proceeds
• Brokered execution through TD Securities (USA) LLC reduces settlement uncertainty
• Original acquisition date (03/15/2016) and nature (executive deferred compensation) are disclosed

Negative

• Multiple recent substantial insider sales from 09/09/2025 to 10/03/2025 may increase available float
• Proposed sale of 4,000 shares with $1,798,765.20 market value could exert short‑term selling pressure
• No statement of total remaining insider holdings beyond the single outstanding shares row, limiting view of remaining insider exposure

Insights

Insider Transactions Analyst

Large, regular insider sales were disclosed across September–early October 2025.

The filing shows a proposed sale of $1,798,765.20 for 4,000 shares to be executed on 10/06/2025 and documents multiple prior sales by the same person dated from 09/09/2025 to 10/03/2025. The original holding was acquired on 03/15/2016 under an executive deferred compensation arrangement.

These disclosures increase transparency about share disposition. Watch trading volumes and end‑of‑plan sell schedules over the next 30 days to see whether sales continue at similar cadence.

Market Impact Analyst

Repeated daily sales of several thousand shares may weigh on short‑term liquidity and price.

The notice lists repeated single‑day sales of 4,000 shares (and one 8,000‑share sale) with gross proceeds reported for each date, executed through TD Securities (USA) LLC. Each disclosed sale shows material cash amounts, indicating notable insider monetization activity over recent weeks.

If similar sales continue, monitor daily volume and price action over the next 1–2 weeks for potential downward pressure; absent other corporate news, the primary driver will be supply from insider sales documented here.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	TD SECURITIES (USA) LLC 125 PARK AVE, 20th Floor NEW YORK NY 10017	4000	1798765.20	45230000	10/06/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	03/15/2016	Executive Deferred Compensation	Martine Rothblatt			294000	03/15/2016	Shares exercised via vested options and payment made via common shares

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/09/2025	8000	3188374.33
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/10/2025	4000	1594872.82
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/11/2025	4000	1588904.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/12/2025	4000	1615897.79
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/15/2025	4000	1591535.70
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/16/2025	4000	1601062.04
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/17/2025	4000	1600686.85
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/18/2025	4000	1617665.13
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/19/2025	4000	1644310.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/22/2025	4000	1669212.50
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/23/2025	4000	1672592.50
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/24/2025	4000	1736488.50
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/25/2025	4000	1723739.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/26/2025	4000	1712891.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/29/2025	4000	1702526.76
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/30/2025	4000	1691357.50
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	10/01/2025	4000	1701796.53
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	10/02/2025	4000	1739525.20
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	10/03/2025	4000	1784847.20

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did United Therapeutics (UTHR) Form 144 disclose?

The Form 144 discloses a proposed sale of 4,000 common shares through TD Securities (USA) LLC on 10/06/2025 with an aggregate market value of $1,798,765.20.

Who is the seller named in the filing for UTHR?

The filer is identified as Martine Rothblatt, with original acquisition of the reported shares on 03/15/2016 via executive deferred compensation.

Were there recent sales by the same person before this Form 144?

Yes. The filing lists multiple sales dated between 09/09/2025 and 10/03/2025, including an 8,000‑share sale on 09/09/2025 and repeated 4,000‑share sales on other dates, each with gross proceeds shown.

How many shares outstanding does the filing show?

The securities table shows 45,230,000 shares outstanding in the same row as the proposed sale.

Which broker will handle the proposed sale?

The proposed sale lists TD Securities (USA) LLC at 125 Park Ave, New York, NY as the broker.